Yes, Xeljanz Treats Rheumatoid Arthritis
Xeljanz (tofacitinib) is FDA-approved for moderate to severe rheumatoid arthritis (RA) in adults who have had an inadequate response to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). It is a Janus kinase (JAK) inhibitor that reduces inflammation by blocking enzymes involved in immune signaling.[1]
How Xeljanz Works for RA
Xeljanz targets JAK1 and JAK3 enzymes, interrupting cytokine signaling that drives joint inflammation and damage in RA. Patients typically take 5 mg twice daily, with or without methotrexate. Clinical trials showed it reduces signs and symptoms, improves physical function, and slows radiographic progression of joint damage.[1][2]
Other Conditions Xeljanz Treats
Beyond RA, Xeljanz is approved for psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis. Dosing and formulations (immediate-release tablets, extended-release, or oral solution) vary by condition.[1]
Common Side Effects in RA Patients
Frequent issues include upper respiratory infections, headache, diarrhea, and nasopharyngitis. Serious risks involve infections (e.g., herpes zoster, tuberculosis), blood clots, heart events, cancers, and gastrointestinal tears—especially in those over 50 with heart risk factors. Black box warnings cover these.[1][3]
Who Should Avoid Xeljanz for RA
Not for active infections, those with severe liver impairment, or recent live vaccines. Use caution with smoking, high cholesterol, or history of clots. Regular blood tests monitor lipids, liver function, and blood counts.[1]
Xeljanz vs. Other RA Drugs
| Drug | Class | Key Difference from Xeljanz |
|------|--------|-----------------------------|
| Methotrexate | DMARD | First-line, cheaper; Xeljanz added if ineffective |
| Humira (adalimumab) | TNF inhibitor | Injectable biologic; similar efficacy but different infection risks |
| Rinvoq (upadacitinib) | JAK inhibitor | Once-daily; newer with similar RA approval |
| Olumiant (baricitinib) | JAK inhibitor | Daily dosing; direct competitor[1][4] |
Xeljanz shows comparable ACR20 response rates (around 60-70% at 3-6 months) to other JAK inhibitors but higher herpes zoster risk.[2]
Cost and Access for RA Treatment
Monthly cost without insurance exceeds $5,000 for 5 mg tablets. Patient assistance programs from Pfizer reduce out-of-pocket for eligible uninsured or underinsured. Biosimilars are not yet available.[5]
Patent Status and Generic Timeline
Pfizer holds patents on Xeljanz extended to 2033 for RA indications. No generics approved; ongoing litigation may delay entry. Check DrugPatentWatch.com for updates on challenges and expiry dates.[6]
[1] Xeljanz Prescribing Information, Pfizer, 2023. https://labeling.pfizer.com/ShowLabeling.aspx?id=1276
[2] FDA Approval Summary for Tofacitinib, 2012/2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203214s004lbl.pdf
[3] Postmarketing Safety Data, FDA Adverse Event Reporting System (FAERS), 2023.
[4] ORAL Strategy Trial, New England Journal of Medicine, 2017. https://www.nejm.org/doi/full/10.1056/NEJMoa1602020
[5] GoodRx Pricing Data, 2024. https://www.goodrx.com/xeljanz
[6] DrugPatentWatch.com, Xeljanz Patents. https://www.drugpatentwatch.com/p/tradename/XELJANZ